These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 29860435)

  • 1. TNF-anti-TNF Immune Complexes Inhibit IL-12/IL-23 Secretion by Inflammatory Macrophages via an Fc-dependent Mechanism.
    Bloemendaal FM; Koelink PJ; van Schie KA; Rispens T; Peters CP; Buskens CJ; van der Bilt JD; Bemelman WA; Korf H; Sabino JG; Ponsioen CY; Te Velde AA; D'Haens GRAM; Vermeire S; van den Brink GR; Wildenberg ME
    J Crohns Colitis; 2018 Aug; 12(9):1122-1130. PubMed ID: 29860435
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A PEGylated Fab' fragment against tumor necrosis factor for the treatment of Crohn disease: exploring a new mechanism of action.
    Bourne T; Fossati G; Nesbitt A
    BioDrugs; 2008; 22(5):331-7. PubMed ID: 18778114
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mechanism of Action of Anti-TNF Therapy in Inflammatory Bowel Disease.
    Levin AD; Wildenberg ME; van den Brink GR
    J Crohns Colitis; 2016 Aug; 10(8):989-97. PubMed ID: 26896086
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mechanism of action of certolizumab pegol (CDP870): in vitro comparison with other anti-tumor necrosis factor alpha agents.
    Nesbitt A; Fossati G; Bergin M; Stephens P; Stephens S; Foulkes R; Brown D; Robinson M; Bourne T
    Inflamm Bowel Dis; 2007 Nov; 13(11):1323-32. PubMed ID: 17636564
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-tumor necrosis factor-α antibodies induce regulatory macrophages in an Fc region-dependent manner.
    Vos AC; Wildenberg ME; Duijvestein M; Verhaar AP; van den Brink GR; Hommes DW
    Gastroenterology; 2011 Jan; 140(1):221-30. PubMed ID: 20955706
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antibodies against tumor necrosis factor (TNF) induce T-cell apoptosis in patients with inflammatory bowel diseases via TNF receptor 2 and intestinal CD14⁺ macrophages.
    Atreya R; Zimmer M; Bartsch B; Waldner MJ; Atreya I; Neumann H; Hildner K; Hoffman A; Kiesslich R; Rink AD; Rau TT; Rose-John S; Kessler H; Schmidt J; Neurath MF
    Gastroenterology; 2011 Dec; 141(6):2026-38. PubMed ID: 21875498
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular mechanisms of action of anti-TNF-α agents - Comparison among therapeutic TNF-α antagonists.
    Mitoma H; Horiuchi T; Tsukamoto H; Ueda N
    Cytokine; 2018 Jan; 101():56-63. PubMed ID: 27567553
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fc gamma receptor CD64 modulates the inhibitory activity of infliximab.
    Wojtal KA; Rogler G; Scharl M; Biedermann L; Frei P; Fried M; Weber A; Eloranta JJ; Kullak-Ublick GA; Vavricka SR
    PLoS One; 2012; 7(8):e43361. PubMed ID: 22937039
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-Tumor Necrosis Factor With a Glyco-Engineered Fc-Region Has Increased Efficacy in Mice With Colitis.
    Bloemendaal FM; Levin AD; Wildenberg ME; Koelink PJ; McRae BL; Salfeld J; Lum J; van der Neut Kolfschoten M; Claassens JW; Visser R; Bentlage A; D'Haens GRAM; Verbeek JS; Vidarsson G; van den Brink GR
    Gastroenterology; 2017 Nov; 153(5):1351-1362.e4. PubMed ID: 28756234
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-TNF therapy in IBD exerts its therapeutic effect through macrophage IL-10 signalling.
    Koelink PJ; Bloemendaal FM; Li B; Westera L; Vogels EWM; van Roest M; Gloudemans AK; van 't Wout AB; Korf H; Vermeire S; Te Velde AA; Ponsioen CY; D'Haens GR; Verbeek JS; Geiger TL; Wildenberg ME; van den Brink GR
    Gut; 2020 Jun; 69(6):1053-1063. PubMed ID: 31506328
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fc Receptor-mediated Effector Function Contributes to the Therapeutic Response of Anti-TNF Monoclonal Antibodies in a Mouse Model of Inflammatory Bowel Disease.
    McRae BL; Levin AD; Wildenberg ME; Koelink PJ; Bousquet P; Mikaelian I; Sterman AS; Bryant S; D'Haens G; Kamath R; Salfeld J; van den Brink GR
    J Crohns Colitis; 2016 Jan; 10(1):69-76. PubMed ID: 26429698
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Proteolytic cleavage and loss of function of biologic agents that neutralize tumor necrosis factor in the mucosa of patients with inflammatory bowel disease.
    Biancheri P; Brezski RJ; Di Sabatino A; Greenplate AR; Soring KL; Corazza GR; Kok KB; Rovedatti L; Vossenkämper A; Ahmad N; Snoek SA; Vermeire S; Rutgeerts P; Jordan RE; MacDonald TT
    Gastroenterology; 2015 Nov; 149(6):1564-1574.e3. PubMed ID: 26170138
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The association of psoriasiform rash with anti-tumor necrosis factor (anti-TNF) therapy in inflammatory bowel disease: a single academic center case series.
    Afzali A; Wheat CL; Hu JK; Olerud JE; Lee SD
    J Crohns Colitis; 2014 Jun; 8(6):480-8. PubMed ID: 24268978
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Infliximab induces downregulation of the IL-12/IL-23 axis in 6-sulfo-LacNac (slan)+ dendritic cells and macrophages.
    Brunner PM; Koszik F; Reininger B; Kalb ML; Bauer W; Stingl G
    J Allergy Clin Immunol; 2013 Nov; 132(5):1184-1193.e8. PubMed ID: 23890755
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Infliximab-Tumor Necrosis Factor Complexes Elicit Formation of Anti-Drug Antibodies.
    Bar-Yoseph H; Pressman S; Blatt A; Gerassy Vainberg S; Maimon N; Starosvetsky E; Ungar B; Ben-Horin S; Shen-Orr SS; Chowers Y;
    Gastroenterology; 2019 Nov; 157(5):1338-1351.e8. PubMed ID: 31401142
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumor necrosis factor-alpha antibody for maintenance of remission in Crohn's disease.
    Behm BW; Bickston SJ
    Cochrane Database Syst Rev; 2008 Jan; (1):CD006893. PubMed ID: 18254120
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Certolizumab pegol does not bind the neonatal Fc receptor (FcRn): Consequences for FcRn-mediated in vitro transcytosis and ex vivo human placental transfer.
    Porter C; Armstrong-Fisher S; Kopotsha T; Smith B; Baker T; Kevorkian L; Nesbitt A
    J Reprod Immunol; 2016 Aug; 116():7-12. PubMed ID: 27123565
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Binding characteristics of tumor necrosis factor receptor-Fc fusion proteins vs anti-tumor necrosis factor mAbs.
    Kohno T; Tam LT; Stevens SR; Louie JS
    J Investig Dermatol Symp Proc; 2007 May; 12(1):5-8. PubMed ID: 17502862
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Formation and clearance of TNF-TNF inhibitor complexes during TNF inhibitor treatment.
    Berkhout LC; I'Ami MJ; Kruithof S; Vogelzang EH; Hooijberg F; Hart MHL; Bentlage AEH; Thomas D; Vermeire S; Vidarsson G; Ten Brinke A; Nurmohamed MT; Wolbink GJ; Rispens T
    Br J Pharmacol; 2024 Apr; 181(8):1165-1181. PubMed ID: 37859583
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Optimizing anti-TNF treatment in inflammatory bowel disease.
    Rutgeerts P; Van Assche G; Vermeire S
    Gastroenterology; 2004 May; 126(6):1593-610. PubMed ID: 15168370
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.